Oxford, UK, 07 Sep 2015 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced the European Patent Office (EPO) has announced its intention to grant a patent for the use of the biomarker HR23B to predict drug sensitivity. HR23B has been shown to be predictive for HDAC and proteasome inhibitor drugs.
Nick La Thangue, CSO of Oxford Cancer Biomarkers, commented: “We are pleased to confirm OCB’s proprietary position for this clinically validated biomarker. OCB has an ever growing portfolio of effective biomarkers including HR23B which we are looking to commercialise over the next 12 to 18 months.”
About Oxford Cancer Biomarkers
Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient. Oxford Cancer Biomarkers is a spin-out of the University of Oxford and has strong links with the Medical Sciences Division. The company was founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University.
For more information, please visit www.oxfordcancerbiomarkers.com or contact Nick La Thangue, CSO, on +44 1865 784743